Tezacaftor

Evidence Level: L5

Predicted Indications: 3

Tezacaftor

Pharmacist Assessment Report

Tezacaftor: From Cystic Fibrosis to HIV Infectious Disease

One-Sentence Summary

Tezacaftor is a CFTR corrector used in fixed-dose combination therapies for cystic fibrosis. The TxGNN model predicts it may be effective for HIV infectious disease, but there are currently no clinical trials and no publications supporting this direction, so the prediction rests on a computational model alone.

Quick Overview

Item	Content
Original Indication	Cystic fibrosis
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	0.9924
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (3 of 3 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	3 (valid: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, tezacaftor is a CFTR corrector that is part of combination therapies (with ivacaftor, with elexacaftor and ivacaftor, and with vanzacaftor and deutivacaftor). Its role in cystic fibrosis is to improve the folding and trafficking of defective CFTR protein to the cell surface.

No mechanistic link to HIV has been established in the data compiled for this report. The TxGNN score is a network-based computational prediction only. Any hypothesis, for example CFTR-related effects on epithelial or immune function, would be speculative and is not supported by trials or literature.

For context, two other predictions were also generated, both with no supporting evidence and a Hold recommendation:

Leprosy (score 0.9914): no trials, no literature, and no evidenced link between CFTR correction and Mycobacterium leprae infection or host response.
Multiple endocrine neoplasia (score 0.9906): these syndromes are driven by germline mutations (such as MEN1 and RET) with no known connection to CFTR folding or trafficking.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 15204F	Alyftrek	Tablet containing 10 mg vanzacaftor (as calcium) with 50 mg tezacaftor and with 125 mg deutivacaftor	Not available in the compiled data
ARTG 11833T	Symdeko	Pack containing 28 tablets tezacaftor 100 mg with ivacaftor 150 mg and 28 tablets ivacaftor 150 mg	Not available in the compiled data
ARTG 12936W	Trikafta	Pack containing 56 tablets elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor 75 mg and 28 tablets ivacaftor 150 mg	Not available in the compiled data

All three products are oral and currently valid.

Safety Considerations

The only interaction record compiled is a pharmacological one: tezacaftor’s target is CFTR (human). No drug-drug interaction data with other medicines were identified.

Please refer to the TGA-approved Product Information (PI) for warnings, contraindications and full interaction information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for HIV infectious disease is supported only by a model score (Evidence Level L5). There are no clinical trials, no publications and no established mechanistic link. The mechanism of action and safety label data are also missing.

To proceed, the following is needed:

Mechanism of action data for tezacaftor (for example from DrugBank)
Warnings and contraindications from the TGA-approved Product Information
A plausible biological rationale linking CFTR correction to HIV, supported by preclinical or in vitro studies
Literature and trial registry searches (ClinicalTrials.gov, ANZCTR) for any related studies
Evaluation of route and formulation compatibility for the proposed indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.